Decision-making for Subsequent Therapy for Patients With Recurrent or Advanced Endometrial Cancer Based on the Platinum-free Interval.

Masafumi Yasunaga,Hideaki Yahata,Kaoru Okugawa,Emiko Hori,Kazuhisa Hachisuga,Shoji Maenohara,Keisuke Kodama,Hiroshi Yagi,Tatsuhiro Ohgami,Ichiro Onoyama,Kazuo Asanoma,Kiyoko Kato

American journal of clinical oncology（2023）

引用 0|浏览6

暂无评分

摘要

Pembrolizumab plus lenvatinib seems to be a better treatment choice for patients with REC or AEC with a PFI of <6 months. For a PFI of ≥6 months, pembrolizumab plus lenvatinib or PCC can be used depending on the degree of residual side -effects associated with cytotoxic agents.

查看译文

关键词

recurrent or advanced endometrial cancer, platinum-free interval, second-line therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要